BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 2873001)

  • 1. Effectiveness of omeprazole in seven patients with Zollinger-Ellison syndrome resistant to histamine H2-receptor antagonists.
    Delchier JC; Soule JC; Mignon M; Goldfain D; Cortot A; Travers B; Isal JP; Bader JP
    Dig Dis Sci; 1986 Jul; 31(7):693-9. PubMed ID: 2873001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of acid suppressants in patients with Zollinger-Ellison syndrome.
    Maton PN
    Aliment Pharmacol Ther; 1991; 5 Suppl 1():25-35. PubMed ID: 1679671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.
    Clissold SP; Campoli-Richards DM
    Drugs; 1986 Jul; 32(1):15-47. PubMed ID: 3527658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists.
    Lambers CB; Lind T; Moberg S; Jansen JB; Olbe L
    N Engl J Med; 1984 Mar; 310(12):758-61. PubMed ID: 6142418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome.
    McArthur KE; Collen MJ; Maton PN; Cherner JA; Howard JM; Ciarleglio CA; Cornelius MJ; Jensen RT; Gardner JD
    Gastroenterology; 1985 Apr; 88(4):939-44. PubMed ID: 3972233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Present experiences with omeprazole in the Zollinger-Ellison syndrome.
    Lamers CB
    Scand J Gastroenterol Suppl; 1986; 118():123-8. PubMed ID: 3460167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omeprazole in the Zollinger-Ellison syndrome.
    Bardram L; Stadil F
    Scand J Gastroenterol; 1986 Apr; 21(3):374-8. PubMed ID: 3715402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome.
    Termanini B; Gibril F; Stewart CA; Weber HC; Jensen RT
    Aliment Pharmacol Ther; 1996 Feb; 10(1):61-71. PubMed ID: 8871445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of patients with Zollinger-Ellison syndrome.
    Mignon M; Pospai D; Forestier S; Vatier J; Vallot T
    Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omeprazole in the treatment of Zollinger-Ellison syndrome and histamine H2-antagonist refractory ulcers.
    Meijer JL; Jansen JB; Lamers CB
    Digestion; 1989; 44 Suppl 1():31-9. PubMed ID: 2575060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study.
    Maton PN; Vinayek R; Frucht H; McArthur KA; Miller LS; Saeed ZA; Gardner JD; Jensen RT
    Gastroenterology; 1989 Oct; 97(4):827-36. PubMed ID: 2777040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome.
    Hirschowitz BI; Mohnen J; Shaw S
    Aliment Pharmacol Ther; 1996 Aug; 10(4):507-22. PubMed ID: 8853754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parenteral control of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Vinayek R; Hahne WF; Euler AR; Norton JA; Jensen RT
    Dig Dis Sci; 1993 Oct; 38(10):1857-65. PubMed ID: 8104773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Gastric secretory, ultrastructural and pH changes during prolonged treatment with omeprazole in a severe form of Zollinger-Ellison syndrome].
    Mignon M; Alcabes G; Lehy T; Nguyen Phuoc BK; Vatier J; Bonfils S
    Gastroenterol Clin Biol; 1984 Dec; 8(12):947-54. PubMed ID: 6519403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy.
    Stewart CA; Termanini B; Sutliff VE; Serrano J; Yu F; Gibril F; Jensen RT
    Aliment Pharmacol Ther; 1998 Jan; 12(1):83-98. PubMed ID: 9692706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR
    Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety.
    Metz DC; Strader DB; Orbuch M; Koviack PD; Feigenbaum KM; Jensen RT
    Aliment Pharmacol Ther; 1993 Dec; 7(6):597-610. PubMed ID: 8161665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of omeprazole on acid secretion and acid-related symptoms in patients with Zollinger-Ellison syndrome.
    Bardram L; Stadil F
    Scand J Gastroenterol Suppl; 1989; 166():95-100; discussion 111-3. PubMed ID: 2574912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Famotidine: effective treatment of Zollinger-Ellison syndrome.
    Howard JM; Vinayek R; Maton PN; Wank SA; Gardner JD; Jensen RT
    J Clin Gastroenterol; 1987; 9 Suppl 2():23-5. PubMed ID: 2887615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Maton PN; Gardner JD; Jensen RT
    Gastroenterol Clin North Am; 1989 Dec; 18(4):847-63. PubMed ID: 2575602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.